Effects of Acetylsalicylic Acid Compared With the Combination of Acetylsalicylic Acid + Modified-release Dipyridamole on Serum Thromboxane B2 Formation and Platelet Aggregation in Healthy Volunteers

Inclusion Criteria: * Male or female healthy volunteers aged 20 to 50 years * Clinically normal medical history * Clinically normal findings on physical examination * Capable of comprehending and communicating effectively with the investigator and staff and of providing informed consent * Willing to give informed consent prior to participation in the trial (i.e. prior to any trial-specific procedures) Exclusion Criteria: * Any clinically significant disease. (A significant disease is defined as a disease which in the opinion of the investigator may either put the subject at risk because of participation in the study or a disease which may influence the results of the study or the subject's ability to participate in the study) * Clinically significant abnormal baseline haematology, blood chemistry or urinalysis findings * Serum glutamate-oxaloacetate transferase (SGOT) or serum glutamate-pyruvate transferase (SGPT) \> 80 IU/L, bilirubin \> 34 µmol/L or creatinine \> 176 µmol/L regardless of clinical condition. Repeat laboratory evaluation will not be conducted in these subjects * Use of dipyridamole, aspirin or any non-steroidal anti-inflammatory agent (NSAID) during the previous two weeks * Active peptic ulceration or history of peptic ulcer disease * Known history of or suspected hypersensitivity to dipyridamole, aspirin, any NSAID or any other component of the test drugs * History of any bleeding disorders * History of cerebral haemorrhage * Resting, seated blood pressure less than 90/60 mmHg * Participation in any drug clinical trial within sixteen weeks prior to the start of the trial * Any indication of current or previous abuse of alcohol, solvents or drugs * Any chronic illness * Asthma * Requirement for any other medication one month before or during the study * Pregnant or nursing women or women of childbearing potential not using a medically approved means of contraception (e.g. oral contraceptives, intrauterine devices or surgically sterile) were to be excluded * Previous participation in the randomisation phase of this clinical trial